INT1284

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1976
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 20
Total Number 45
Disease Relevance 36.21
Pain Relevance 14.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Mmp13) extracellular space (Mmp13) extracellular region (Mmp13)
Golgi apparatus (Mmp13) proteinaceous extracellular matrix (Mmp13) lysosome (Mmp13)
Anatomy Link Frequency
cartilage 8
chondrocytes 4
joint 1
plasma 1
articular 1
Mmp13 (Mus musculus)
Pain Link Frequency Relevance Heat
metalloproteinase 403 100.00 Very High Very High Very High
Arthritis 884 99.88 Very High Very High Very High
rheumatoid arthritis 819 99.88 Very High Very High Very High
Potency 7 99.40 Very High Very High Very High
cva 8 99.04 Very High Very High Very High
Inflammation 659 98.76 Very High Very High Very High
cytokine 56 98.56 Very High Very High Very High
Osteoarthritis 373 98.04 Very High Very High Very High
fibrosis 247 97.00 Very High Very High Very High
Calcitonin gene-related peptide 10 96.24 Very High Very High Very High
Disease Link Frequency Relevance Heat
Arthritis 932 99.88 Very High Very High Very High
Rheumatoid Arthritis 819 99.88 Very High Very High Very High
Severe Combined Immunodeficiency 365 99.68 Very High Very High Very High
Pressure And Volume Under Development 37 99.48 Very High Very High Very High
Cv General 3 Under Development 4 99.04 Very High Very High Very High
Hypercalcemia 20 98.96 Very High Very High Very High
Arthropathy 8 98.94 Very High Very High Very High
Hypertrophy 28 98.84 Very High Very High Very High
INFLAMMATION 676 98.76 Very High Very High Very High
Hyperoxia 1 98.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
-induced increase in collagenase activity, but only A1S2 inhibited the spontaneous collagenase activity.
Negative_regulation (inhibited) of collagenase
1) Confidence 0.57 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779427 Disease Relevance 0.07 Pain Relevance 0.21
Effects of the MMP-13 inhibitor in AIA
Negative_regulation (inhibitor) of MMP-13 associated with arthritis
2) Confidence 0.55 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.66 Pain Relevance 0.33
In the AIA model, the MMP-13 inhibitor did not show a significant effect on the destruction process.
Negative_regulation (inhibitor) of MMP-13 associated with arthritis
3) Confidence 0.55 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.69 Pain Relevance 0.58
We observed that the specific MMP-13 inhibitor was effective in destructive models but less effective in inflammatory models.
Negative_regulation (inhibitor) of MMP-13 associated with inflammation
4) Confidence 0.48 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.36 Pain Relevance 0.54
All patients with RA fulfilled the American College of Rheumatology criteria for the classification of RA.8 The MMP-13 selective inhibitor used in this study is described as Compound 2 in a recent publication.7

Immunohistochemistry

Negative_regulation (inhibitor) of MMP-13 associated with rheumatoid arthritis
5) Confidence 0.48 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.07 Pain Relevance 0.41
This was associated with a downregulation of collagenases MMP-13 and MMP-1, proinflammatory cytokines IL-1?
Negative_regulation (downregulation) of collagenase associated with metalloproteinase and cytokine
6) Confidence 0.42 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206385 Disease Relevance 0.74 Pain Relevance 0.47
Two examples of nonpeptidyl hydroxamate inhibitors are prinomastat (AG-3340; Agouron, San Diego, USA) inhibitor, which is selective for gelatinases over collagenases, and Ro32-3555 (Roche, Basel, Switzerland), which is an effective inhibitor of collagenases but has less potency against MMP-2 and MMP-3.


Negative_regulation (inhibitor) of collagenase associated with potency
7) Confidence 0.41 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC154424 Disease Relevance 0.35 Pain Relevance 0.23
Previous studies, however, have shown that multiple tetracyclines can inhibit collagenase MMPs via down-regulation of gene expression in a cellular model of rheumatoid arthritis using cultured chondrocytes [33] and that pre-treatment with minocycline down-regulates pro-MMP expression after permanent cerebral ischemia [17].
Negative_regulation (inhibit) of collagenase in chondrocytes associated with cv general 4 under development, ischemia and rheumatoid arthritis
8) Confidence 0.41 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1543649 Disease Relevance 0.53 Pain Relevance 0.19
The MMP-13 inhibitor was administered orally for 60 days (60 mg/kg/day) without any toxic side effects considering behaviour and weight.
Negative_regulation (inhibitor) of MMP-13
9) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.63 Pain Relevance 0.14
This might explain why the specific MMP-13 inhibitor was more effective in the non-inflammatory SCID mouse co-implantation model.
Negative_regulation (inhibitor) of MMP-13 associated with inflammation and severe combined immunodeficiency
10) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.57 Pain Relevance 0.53
Effects of the MMP-13 inhibitor on the SCID-mouse model of RA
Negative_regulation (inhibitor) of MMP-13 associated with severe combined immunodeficiency and rheumatoid arthritis
11) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.70 Pain Relevance 0.16
In this study, we evaluated the effects of a novel MMP-13 inhibitor on cartilage and joint destruction using different models of RA—the SCID mouse co-implantation model, the CIA model and the AIA model.
Negative_regulation (inhibitor) of MMP-13 in joint associated with severe combined immunodeficiency, rheumatoid arthritis and arthritis
12) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.37 Pain Relevance 0.53
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis

Objective

Negative_regulation (inhibitor) of MMP-13 associated with rheumatoid arthritis
13) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Title Doc Link PMC2925150 Disease Relevance 0.99 Pain Relevance 0.46
This focuses specifically on the invasion of human RASF into human cartilage and is therefore relevant for the analysis of processes that interfere with destruction.13 The specific MMP-13 inhibitor decreased cartilage destruction in both, the SCID mouse and the CIA model.
Negative_regulation (inhibitor) of MMP-13 in cartilage associated with severe combined immunodeficiency and arthritis
14) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.64 Pain Relevance 0.58
In conclusion, in contrast to the other two animal models of arthritis, the MMP-13 inhibitor did not show significant effects in the AIA model.


Negative_regulation (inhibitor) of MMP-13 associated with arthritis
15) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 1.23 Pain Relevance 0.50
In the CIA model of RA, the MMP-13 inhibitor resulted in a significant and dose-dependent decrease in clinical symptoms as well as of cartilage erosion by 38% (30 mg/kg), 28% (10 mg/kg) and 21% (3 mg/kg).
Negative_regulation (inhibitor) of MMP-13 in cartilage associated with rheumatoid arthritis and arthritis
16) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Abstract Doc Link PMC2925150 Disease Relevance 1.05 Pain Relevance 0.48
In this study, we analysed a novel highly selective MMP-13 inhibitor which differs from previous MMP inhibitors, because it does not bind to the catalytic zinc ion and is non-competitive with respect to substrate binding.7 Unlike other MMP inhibitors this novel MMP-13 inhibitor binds deeply into the S1?
Negative_regulation (inhibitor) of MMP-13
17) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.95 Pain Relevance 0.43
To analyse the anti-destructive effects of this novel MMP-13 inhibitor, we decided to use a prophylactic approach for all three animal models and therefore we applied the drug before the appearance of the disease, which provides more information about the pathogenesis of the disease.
Negative_regulation (inhibitor) of MMP-13 associated with disease
18) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.95 Pain Relevance 0.33
In this study, we analysed a novel highly selective MMP-13 inhibitor which differs from previous MMP inhibitors, because it does not bind to the catalytic zinc ion and is non-competitive with respect to substrate binding.7 Unlike other MMP inhibitors this novel MMP-13 inhibitor binds deeply into the S1?
Spec (analysed) Negative_regulation (inhibitor) of MMP-13
19) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.85 Pain Relevance 0.39
Effects of the MMP-13 inhibitor in CIA
Negative_regulation (inhibitor) of MMP-13 associated with arthritis
20) Confidence 0.41 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2925150 Disease Relevance 0.71 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox